TABLE 3.
Clinical impact of plasma mNGS testing (n = 147)
| Categories of clinical impact | No. (%)of plasma mNGS Tests |
|---|---|
| Positive impact | 83 (57.1%) |
| Enabled new diagnosis of infection and initiation of targeted therapy | 32 (21.8%) |
| Enabled earlier diagnosis than conventional methods and initiation of targeted therapy | 25 (17.0%) |
| Enabled new diagnosis of infection and escalation of therapy | 8 (5.4%) |
| Enabled new diagnosis of infection and de-escalation of therapy | 7 (4.8%) |
| Enabled ruling-out of Infection and initiation of noninfectious therapy | 11 (7.5%) |
| No impact | 63 (42.9%) |
| Redundant information, antibiotics and clinical plan were not changed | 28 (19%) |
| A negative result with no clinical significance | 16 (10.9%) |
| No relevant pathogen (considered transient unrelated bacteremia) | 6 (4.1%) |
| No relevant pathogen (considered contamination) | 6 (4.1%) |
| No relevant pathogen (considered pathogen associated with established chronic infection) | 4 (2.7%) |
| Patient forgoes further treatment (discharge or death) | 3 (2.0%) |
| Negative impact | 1 (0.7%) |
| Lead to unnecessary treatment | 1 (0.7%) |